Naproxen
( DrugBank: Naproxen / KEGG DRUG: Naproxen, Naproxen sodium )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis | 1 |
| 46 | Malignant rheumatoid arthritis | 20 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 107 | Juvenile idiopathic arthritis | 4 |
| 271 | Ankylosing spondylitis | 12 |
13. Multiple sclerosis
Clinical trials : 3,685 / Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
46. Malignant rheumatoid arthritis
Clinical trials : 4,543 / Drugs : 2,251 - (DrugBank : 390) / Drug target genes : 198 - Drug target pathways : 232
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
107. Juvenile idiopathic arthritis
Clinical trials : 477 / Drugs : 232 - (DrugBank : 53) / Drug target genes : 66 - Drug target pathways : 160
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
271. Ankylosing spondylitis
Clinical trials : 603 / Drugs : 302 - (DrugBank : 69) / Drug target genes : 40 - Drug target pathways : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|